OPKO Health to Sell BioReference Lab Assets to Labcorp for $722 Million Plus Earnout
OPKO Health entered an asset purchase agreement to sell BioReference’s clinical and anatomic pathology lab testing assets to Labcorp for $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million over up to ten years tied to 4Kscore sales.